# US 2025/0084489 A1 · Method of predicting survival rates for cancer patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084489 A1
- Document ID: US20250084489A1
- Status: Published application
- Kind: A1
- Application number: 18/960,456
- Filed: 2024-11-26
- Published: 2025-03-13
- Earliest claimed: 2019-02-01
- Assignees: The Francis Crick Institute Limited; University College London
- Applicants: The Francis Crick Institute Limited; University College London
- Inventors: Robert Charles Swanton; Dhruva Biswas; Nicholas McGranahan; Nicolai Juul Birkbak
- Web page: https://patentgrep.com/patent/US20250084489A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention provides a method for generating a biomarker signature for a subject with cancer. The method comprises calculating an intra-tumour heterogeneity measure and an inter-tumour heterogeneity measure for a plurality of genes. This is done using training data from a plurality of subjects who have had cancer, where the training data comprises gene expression data for a plurality of genes for each subject. A biomarker signature is generated by applying a heterogeneity filter to select genes having both an intra-tumour heterogeneity below an intra-tumour heterogeneity threshold and an inter-tumour heterogeneity above an inter-tumour heterogeneity threshold.

## Claims

### Claim at position 1

1-54. (canceled)

### Claim 55

A method for generating a biomarker signature for a subject with cancer, the method comprising:
generating training data from a plurality of subjects who have had cancer, the training data comprising gene expression data for a plurality of genes for each of the plurality of subjects;
calculating both an intra-tumour heterogeneity measure and an inter-tumour heterogeneity measure for each gene in the plurality of genes based on the gene expression data; and
applying a heterogeneity filter to select genes having both an intra-tumour heterogeneity below an intra-tumour heterogeneity threshold and an inter-tumour heterogeneity above an inter-tumour heterogeneity threshold;
wherein the biomarker signature comprises at least some of the selected genes.

### Claim 56 (depends on 55)

The method of claim 55, further comprising:
calculating a concordance score for each gene; and
applying a concordance filter to select genes having a concordance score below a concordance threshold.

### Claim 57 (depends on 56)

The method of claim 56, wherein the concordance score is calculated for the selected genes after applying the heterogeneity filter.

### Claim 58 (depends on 55)

The method of claim 55, wherein the intra-tumour heterogeneity measure for each gene is calculated by:
obtaining values for the gene expression of each gene at multiple locations within the same tumour,
calculating, for each tumour, a measure which is indicative of the obtained gene expression values of each gene, and
obtaining the intra-tumour heterogeneity measure as the average value of the indicative measure for each gene in each tumour.

### Claim 59 (depends on 58)

The method of claim 58, wherein the measure which is indicative of the gene expression values is selected from the standard deviation, the median absolution deviation and the coefficient of variation.

### Claim 60 (depends on 55)

The method of claim 55, wherein the inter-tumour heterogeneity measure is calculated by:
obtaining values for the gene expression at one of multiple regions in a tumour for each subject; and
taking the standard deviation across the obtained values.

### Claim 61 (depends on 60)

The method of claim 60, further comprising iterating the obtaining and taking steps multiple times and averaging the standard deviation across iterations to obtain the inter-tumour heterogeneity measure.

### Claim 62 (depends on 55)

The method of claim 55, wherein the biomarker signature is prognostic, and the method further comprises:
generating training data comprising associated survival data for each of the plurality of subjects;
calculating a prognostic measure for each of the plurality of genes based on the survival data; and
applying a prognostic filter to select genes having a prognostic measure above a prognostic threshold.

### Claim 63 (depends on 62)

The method of claim 62, wherein the prognostic measure is calculated using Cox univariate regression analysis.

### Claim 64 (depends on 55)

The method of claim 55, wherein the biomarker signature is predictive for a response of a subject to a particular treatment, and the method further comprises:
generating training data comprising associated response data for each of the plurality of subjects;
calculating a predictive measure for each of the plurality of genes based on the response data; and
applying a predictive filter to select genes having a predictive measure above a predictive threshold.

### Claim 65 (depends on 55)

A method for providing a treatment for a subject with cancer, the method comprising:
contacting a biological sample from the subject with reagents that specifically bind to each member of a panel of biomarkers in the signature generated using the method of claim 55;
determining a riskscore of the subject based on the nucleic acid levels of expression of the biomarkers in the samples;
providing a prognosis for the cancer based on the risk score of the subject; and
determining a treatment based on the prognosis.

### Claim 66 (depends on 55)

A composition comprising a panel of reagents that specifically bind to each member of a panel of biomarkers in the signature generated using the method of claim 55.
